|Videos|December 11, 2020

Implications of Expanding Use of CAR T-Cell Therapy in Relapsed/Refractory Non-Hodgkin Lymphoma (NHL)

A discussion on the clinical impact of chimeric antigen receptor (CAR) T-cell therapy in relapsed/refractor (R/R) non-Hodgkin lymphoma and the role of expanding CAR T administration into the community practice setting.

Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.

Related to this article

April 3rd, 2026

ImmunoLogic, Episode 9: "Rewiring Immunotherapy for High-Risk Neuroblastoma" With Kristopher R. Bosse, MD

In episode 9 of ImmunoLogic, Kristopher Bosse, MD, and the cohosts discussed how immunotherapy is reshaping treatment for high-risk neuroblastoma.

September 2nd, 2026

Novartis, BMS Pause Autoimmune CAR-T Trials After Safety Events

Novartis suspended several autoimmune and neurology trials of rap-cel after 3 patient deaths linked to immune effector cell-associated hemophagocytic syndrome, and BMS separately paused zola-cel studies after observing inflammatory safety events.

August 17th, 2026

J&J Secures $2.58B Option to Acquire Sail Biomedicines

Johnson & Johnson secures an exclusive option to acquire Sail Biomedicines for $2.58 billion, backing the biotech's in vivo CAR T platform for immune-mediated disease.